无码日韩精品91超碰,免费一级毛片

嗎啉硝唑

NMR下載 COA and HPLC MSDS下載
names：
Morinidazole
CAS號(hào)：
92478-27-8
MDL Number： MFCD28386297
MF(分子式)： C11H18N4O4 MW(分子量)： 270.29
EINECS: Reaxys Number:
Pubchem ID:11644726 Brand:BIOFOUNT

嗎啉硝唑(92478-27-8,Morinidazole)是一種新型的5-硝基咪唑抗微生物藥物，嗎啉硝唑可通過N +-葡萄糖醛酸化和硫酸化作用在人體中廣泛代謝，嗎啉硝唑用于治療細(xì)菌感染，包括由厭氧菌引起的闌尾炎和盆腔炎。

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	特價(jià)(￥)	庫存描述	數(shù)量	總計(jì) (￥)
YZM000178-5mg	5mg	>98.0%	￥ 3412.50	￥ 3412.50		2-3天	- +	￥ 0.00

大包裝詢價(jià) 提供各種包裝，敬請(qǐng)垂詢
收藏商品商品點(diǎn)評(píng) 加入購物車立即購買

快速詢價(jià)

收起

你想詢價(jià)的產(chǎn)品

*產(chǎn)品名稱：

CAS號(hào)：

產(chǎn)品編號(hào)：

需求描述：

請(qǐng)準(zhǔn)確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢價(jià)

中文別名	嗎啉硝唑(92478-27-8);森硝唑;莫立硝唑;莫利硝唑;1-（2-甲基-5-硝基-1H-咪唑-1-基）-3-嗎啉代丙烷-2-醇;α-[（2-甲基-5-硝基-1H-咪唑-1-基）甲基] -4-嗎啉乙醇;
英文別名	Morinidazole(92478-27-8);morinidazole;1-(2-Methyl-5-nitro-1H-imidazol-1-yl)-3-morpholinopropan-2-ol;alpha-[(2-Methyl-5-nitro-1H-imidazol-1-yl)methyl]-4-morpholineethanol;
CAS號(hào)	92478-27-8
Inchi	InChI=1S/C11H18N4O4/c1-9-12-6-11(15(17)18)14(9)8-10(16)7-13-2-4-19-5-3-13/h6,10,16H,2-5,7-8H2,1H3
InchiKey	GAZGHCHCYRSPIV-UHFFFAOYSA-N
分子式 Formula	C11H18N4O4
分子量 Molecular Weight	270.29
溶解度Solubility	生物體外In Vitro:DMSO溶解度≥ 100 mg/mL(369.97 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性狀	固體粉末,Power
儲(chǔ)藏條件 Storage conditions	-20°C冰柜, 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月

嗎啉硝唑(92478-27-8,Morinidazole)實(shí)驗(yàn)注意事項(xiàng)：
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡，穿戴防護(hù)服和口罩，佩戴手套，避免與皮膚接觸。
2.實(shí)驗(yàn)過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對(duì)實(shí)驗(yàn)人員造成傷害
3.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲(chǔ)，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags:嗎啉硝唑試劑,嗎啉硝唑雜質(zhì),嗎啉硝唑中間體,嗎啉硝唑密度,嗎啉硝唑溶解度,嗎啉硝唑旋光度,嗎啉硝唑閃點(diǎn),嗎啉硝唑熔點(diǎn),嗎啉硝唑購買,

產(chǎn)品說明	嗎啉硝唑(92478-27-8,Morinidazole)用于治療細(xì)菌感染，包括厭氧菌引起的盆腔炎和闌尾炎。
Introduction	嗎啉硝唑(92478-27-8,Morinidazole)is a novel 5itroimidazole antimicrobial drug that undergoes extensive metabolism in humans via N+lucuronidation and sulfation,
Application1	(嗎啉硝唑,92478-27-8)Morinidazole for the treatment of bacterial infections including appendicitis and pelvic inflammatory disease (PID) caused by anaerobic bacteria.
Application2	嗎啉硝唑(92478-27-8,Morinidazole)是一種新型的5-硝基咪唑抗微生物藥物，可通過N +-葡萄糖醛酸化和硫酸化作用在人體中廣泛代謝，用于治療細(xì)菌感染，包括由厭氧菌引起的闌尾炎和盆腔炎。
Application3

嗎啉硝唑(92478-27-8,Morinidazole)藥理學(xué)：

嗎啉硝唑是一種新型的5-硝基咪唑抗微生物藥。嗎啉硝唑通過N +-葡萄糖醛酸化和硫酸化在人類中進(jìn)行廣泛的代謝。嗎啉硝唑用于治療細(xì)菌感染，包括厭氧菌引起的盆腔炎和闌尾炎。

警示圖
危險(xiǎn)性	warning
危險(xiǎn)性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對(duì)身體有害
安全防護(hù)	P264處理后徹底清洗+P280戴防護(hù)手套/穿防護(hù)服/戴防護(hù)眼罩/戴防護(hù)面具+P305如果進(jìn)入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護(hù)理
備注	實(shí)驗(yàn)過程中防止吸入、食入，做好安全防護(hù)

Zhong K, et al. Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearanceof the conjugated metabolites. Antimicrob Agents Chemother. 2014 Jul;58(

Increased Plasma Exposures of Conjugated Metabolites of Morinidazole in Renal Failure Patients: A Critical Role of Uremic Toxins PMID 28314825; Drug metabolism and disposition: the biological fate of

Metabolism and pharmacokinetics of morinidazole in humans: identification of diastereoisomeric morpholine N+-glucuronides catalyzed by UDP glucuronosyltransferase 1A9 PMID 22184458; Drug metabolism an

Simultaneous determination of morinidazole, its N-oxide, sulfate, and diastereoisomeric N(+)-glucuronides in human plasma by liquid chromatography-tandem mass spectrometry PMID 23122401; Journal of ch

Simultaneous quantification of metronidazole, tinidazole, ornidazole and morinidazole in human saliva PMID 22658465; Journal of chromatography. B, Analytical technologies in the biomedical and life sc

嗎啉硝唑(92478-27-8,Morinidazole)參考文獻(xiàn)：

1.Efficacy and safety of morinidazole in pelvic inflammatory disease: results of a multicenter, double-blind, randomized trial.
Cao C;Luo A;Wu P;Weng D;Zheng H;Wang S Eur J Clin Microbiol Infect Dis. 2017 Jul;36(7):1225-1230. doi: 10.1007/s10096-017-2913-z. Epub 2017 Mar 6.

This multicenter, double-blind, randomized, parallel-group, non-inferiority study compared the efficacy and safety of morinidazole with those of ornidazole in women with pelvic inflammatory disease. Women from 18 hospitals in China received a 14-day course of either intravenous morinidazole, 500 mg twice daily (n = 168), or intravenous ornidazole, 500 mg twice daily (n = 170). A total of 312 of 338 patients in the full analysis set (FAS) (92.3%) were included in the per protocol set (PPS) analyses, 61 (19.6%) of whom were included in the microbiologically valid (MBV) population. The clinical resolution rates in the PPS population at the test of cure (TOC, primary efficacy end point, 7-30 days post-therapy) visit were 96.86% (154/159) for morinidazole and 96.73% (148/153) for ornidazole (95% CI: -3.79% to 4.03%). The bacteriological success rates in the MBV population at the TOC visit were 100% (32/32) for morinidazole and 89.66% (26/29) for ornidazole (95% CI: -16.15% to 11.21%). Drug-related adverse events occurred less frequently with morinidazole (32.74%, 55/168) than with ornidazole (47.06%, 80/170) (p < 0.01). For women with pelvic inflammatory disease, twice-daily morinidazole for 14 days was clinically and bacteriologically as efficacious as twice-daily ornidazole for 14 days, while the former was associated with fewer drug-related adverse events than the latter.

2.Simultaneous quantification of metronidazole, tinidazole, ornidazole and morinidazole in human saliva.
Wang Y;Zhang P;Jiang N;Gong X;Meng L;Wang D;Ou N;Zhang H J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 15;899:27-30. doi: 10.1016/j.jchromb.2012.04.032. Epub 2012 May 15.

The aim of this study was to develop a rapid and sensitive method for the simultaneous quantification of metronidazole (MEZ), tinidazole (TNZ), ornidazole (ONZ) and morinidazole (MNZ) in human saliva. A reversed-phase high-performance liquid chromatography (HPLC) method with ultraviolet (UV) detection at 318 nm was carried out on a C18 column, using a mixture of potassium dihydrogen phosphate buffer, acetonitrile, and methanol (55:15:30, v/v/v) as a mobile phase with a flow rate of 1.0 ml/min. The saliva samples (100 μl) were firstly deproteinized by precipitation with methanol (400 μl), after which they were centrifuged and the supernatants were directly injected into the HPLC system. This method produced linear responses in the concentration ranges of 25.2-5040.0, 23.9-4790.0, 25.4-5080.0, 25.0-5000.0 ng/ml with detection limits of 6.0, 17.6, 10.0 and 11.3 ng/ml for MEZ, TNZ, ONZ and MNZ (S/N=3), respectively. The methods were validated in terms of intra- and inter-batch precision (within 7.3% and 9.1%, respectively), accuracy, linearity, recovery and stability. The study proved that HPLC is both sensitive and selective for the simultaneous quantification of MEZ, TNZ, ONZ and MNZ in human saliva using a single mobile phase.

3.Investigation of the effects of 24 bio-matrices on the LC-MS/MS analysis of morinidazole.
Lv W Talanta. 2010 Jan 15;80(3):1406-12. doi: 10.1016/j.talanta.2009.09.043.

This study compares and evaluates the effect of various matrices on liquid chromatography (LC) coupled with tandem mass spectrometry (MS/MS) analysis. Permanent post-column infusion (PCI) was used to quantify matrix effects. In this way, the suppressed or enhanced signal of the target material resulting from different co-eluting matrix components could be assessed. Twenty-four biological samples from in vivo and in vitro experiments were selected for this study. In addition, 7 sample components were further analyzed after sample preparation by protein precipitation. Multiple regression analysis was used to investigate the collinear relationship between matrix effects and co-eluted components at different time intervals. We found that salt was the dominant factor which impacted changes in signal detection. In order to eliminate it, we used ammonium formate as a modifier of the mobile phase which resulted in charge-state redistribution profiles so that a homogeneous matrix formed. By employing pulse gradient chromatography in the presence of 5mM ammonium formate, favorable improvements of enhanced signal intensity and reduced matrix effects were obtained. These experiments also indicated the feasibility of using analogue IS during bio-analysis which contributed to an overall faster assay that would be suitable for drug discovery and development purposes.

對(duì)不起，暫無產(chǎn)品評(píng)價(jià)！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開